Evelyn Van Den Tweel

Evelyn Van Den Tweel

Company: Byondis

Job title: Project Leader, Clinical Development


Primary Outcome of the Phase III SYD985.002/TULIP® Study Comparing [vic-]trastuzumab duocarmazine to Physician’s Choice Treatment in Patients with Pre-treated HER2-positive Locally Advanced or Metastatic Breast Cancer 8:30 am

-The TULIP® study met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement over physician’s choice. -The preliminary overall survival (OS) results are supportive. -Safety data obtained in the trial will be discussedRead more

day: day 2 opps
day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.